Your shopping cart is currently empty

NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $48 | In Stock | In Stock | |
| 25 mg | $98 | In Stock | In Stock | |
| 50 mg | $158 | In Stock | In Stock | |
| 100 mg | $259 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $30 | In Stock | In Stock |
| Description | NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively) |
| Targets&IC50 | mGluR1:5.2nM , mGluR5:82 nM |
| In vitro | Treatment of NPS2390 was conducive to inhibit the proliferation and reverse phenotypic modulation of PASMCs by regulating autophagy levels. |
| Molecular Weight | 307.39 |
| Formula | C19H21N3O |
| Cas No. | 226878-01-9 |
| Smiles | O=C(NC12CC3CC(CC(C3)C1)C2)c1cnc2ccccc2n1 |
| Relative Density. | 1.28 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.08 mg/mL (10.02 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.